The Role of Smad3 in the Realization of the Growth Potential of Different Types of Neural Progenitor Cells and the Secretory Function of Neuroglia.

Smad3 committed neuronal progenitors neural stem cells neurodegenerative diseases targeted therapy

Journal

Bulletin of experimental biology and medicine
ISSN: 1573-8221
Titre abrégé: Bull Exp Biol Med
Pays: United States
ID NLM: 0372557

Informations de publication

Date de publication:
02 Jul 2024
Historique:
received: 13 10 2023
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 2 7 2024
Statut: aheadofprint

Résumé

The features of the participation of Smad3 in the functioning of neural stem cells (NSC), neuronal committed precursors (NCP), and neuroglial elements were studied in vitro. It was found that this intracellular signaling molecule enhances the clonogenic and proliferative activities of NCP and inhibits specialization of neuronal precursors. At the same time, Smad3 does not participate in the realization of the growth potential of NSC. With regard to the secretory function (production of neurotrophic growth factors) of neuroglial cells, the stimulating role of Smad3-mediated signaling was shown. These results indicate the promise of studying the possibility of using Smad3 as a fundamentally new target for neuroregenerative agents.

Identifiants

DOI: 10.1007/s10517-024-06126-8 PMID: 38954301
pubmed: 38954301
doi: 10.1007/s10517-024-06126-8
pii: 10.1007/s10517-024-06126-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Zyuz’kov GN, Miroshnichenko LA, Kotlovskaya LY, Chayikovskyi AV. Inhibitors of intracellular signaling molecules: New horizons in drug discovery for the treatment of Alzheimer’s disease. Biointerface Res. Appl. Chem. 2022;13(5):401. https://doi.org/10.33263/BRIAC135.401
Zyuz’kov G. Targeted Regulation of Intracellular Signal Transduction: A New Paradigm for Stimulation of Neurogenesis in Alzheimer’s Disease. Curr. Drug Targets. 2023;24(10):777-780. https://doi.org/10.2174/1389450124666230719104808
Zyuz’kov GN, Zhdanov VV, Miroshnichenko LA, Polyakova TY, Simanina EV, Danilets MG, Agafonov VI, Stavrova LA. Participation of cAMP-Mediated Signaling Transduction in the Regulation of the Secretory Function of Neuroglia during Ethanol-Induced Neurodegeneration. Bull. Exp. Biol. Med. 2023;175(1):12-16. https://doi.org/10.1007/s10517-023-05800-7
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021;397:1577-1590. https://doi.org/10.1016/S0140-6736(20)32205-4
doi: 10.1016/S0140-6736(20)32205-4 pubmed: 33667416 pmcid: 8354300
Liu DD, He JQ, Sinha R, Eastman AE, Toland AM, Morri M, Neff NF, Vogel H, Uchida N, Weissman IL. Purification and characterization of human neural stem and progenitor cells. Cell. 2023;186(6):1179-1194.e15. https://doi.org/10.1016/j.cell.2023.02.017
doi: 10.1016/j.cell.2023.02.017 pubmed: 36931245 pmcid: 10409303
Zyuz’kov GN, Miroshnichenko LA, Chaikovsky AV, Kotlovskaya LY. The Role of MARK ERK1/2 and p38 in Regulation of Functions of Neural Stem Cells and Neuroglia under Conditions of β-Amyloid-Induced Neurodegeneration. Bull. Exp. Biol. Med. 2022;173(4):424-428. https://doi.org/10.1007/s10517-022-05561-9
Zyuz’kov GN, Miroshnichenko LA, Chayikovskyi AV, Kotlovskaya LY. Nf-κb: A Target for Synchronizing the Functioning Nervous Tissue Progenitors of Different Types in Alzheimer’s Disease. Curr. Mol. Pharmacol. 2023;16(2):234-241. https://doi.org/10.2174/1874467215666220601144727
Zyuz’kov GN, Miroshnichenko LA, Polyakova TYu, Simanina EV. Neuroprotective and Neuroregenerative Effects of Shikonin-mediated Inhibition of NF-κB/Stat3 in Alcoholic Encephalopathy. Lett. Drug Design Discov. 2023;20(12):2045-2054. https://doi.org/10.2174/1570180820666221107112141
Zyuz’kov G, Miroshnichenko L, Chayikovskyi A, Kotlovskaya L. Prospects for the Therapeutic Potential of Inhibitors Targeting JNK and p53 in Alzheimer’s Disease. Adv. Life Sci. 2023;10(2):298-303.
Zyuz’kov GN, Miroshnichenko LA, Kotlovskaya LYu, Chayikovskyi AV. New Insights into Alzheimer’s Drug Discovery Targeting NF-κB. Biointerface Res. Appl. Chem. 2024;14(1):1-13. https://doi.org/10.33263/BRIAC141.018
Zyuz’kov GN, Miroshnichenko LA, Polyakova TYu, Simanina EV, Chayikovskyi AV, Kotlovskaya LYu. Insight into JNK Inhibition-based Strategy for the Treatment of Alzheimer’s Disease. Cur. Enzyme Inhib. 2024;20(1):51-60. https://doi.org/10.2174/1573408019666230816143357
Hiew LF, Poon CH, You HZ, Lim LW. TGF-β/Smad Signalling in Neurogenesis: Implications for Neuropsychiatric Diseases. Cells. 2021;10(6):1382. https://doi.org/10.3390/cells10061382
doi: 10.3390/cells10061382 pubmed: 34205102 pmcid: 8226492
Coatti GC, Paranjapye A, Harris A. Dual SMAD inhibition enhances the longevity of human epididymis epithelial cells. Cell Tissue Res. 2023;391(2):409-417. https://doi.org/10.1007/s00441-022-03712-y
doi: 10.1007/s00441-022-03712-y pubmed: 36454271
Fang X, Gao Y, Li Q. SMAD3 Activation: A Converging Point of Dysregulated TGF-Beta Superfamily Signaling and Genetic Aberrations in Granulosa Cell Tumor Development? Biol. Reprod. 2016;95(5):105. https://doi.org/10.1095/biolreprod.116.143412
doi: 10.1095/biolreprod.116.143412
Rosebrock D, Arora S, Mutukula N, Volkman R, Gralinska E, Balaskas A, Aragonés Hernández A, Buschow R, Brändl B, Müller FJ, Arndt PF, Vingron M, Elkabetz Y. Enhanced cortical neural stem cell identity through short SMAD and WNT inhibition in human cerebral organoids facilitates emergence of outer radial glial cells. Nat. Cell Biol. 2022;24(6):981-995. https://doi.org/10.1038/s41556-022-00929-5
doi: 10.1038/s41556-022-00929-5 pubmed: 35697781 pmcid: 9203281

Auteurs

G N Zyuz'kov (GN)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. zgn@pharmso.ru.

L A Miroshnichenko (LA)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

T Yu Polyakova (TY)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.

E V Simanina (EV)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

A V Chaikovsky (AV)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

V I Agafonov (VI)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.

L A Stavrova (LA)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

E V Udut (EV)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.

A A Churin (AA)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

V V Zhdanov (VV)

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Classifications MeSH